Literature DB >> 6381007

Metabolic alterations after a two-hour nocturnal interruption of a continuous subcutaneous insulin infusion.

A Scheen, M Castillo, B Jandrain, G Krzentowski, P Henrivaux, A S Luyckx, P J Lefèbvre.   

Abstract

In order to evaluate the metabolic consequences of a 2-h nocturnal interruption of continuous subcutaneous insulin infusion (CSII), seven insulin-dependent diabetic patients without residual insulin secretion were investigated. The changes in blood glucose, plasma free insulin, glucagon, free fatty acids, and 3-hydroxybutyrate (3 OH-B) concentrations have been compared during two randomized tests carried out either during the normal functioning of a Mill-Hill pump from 10 p.m. to 8 a.m. (1.00 +/- 0.06 U insulin/h, keeping adequate metabolic control) or during the same conditions but with a deliberate arrest of the pump between 11 p.m. and 1 a.m. Considering the value recorded at 11 p.m. as reference, interruption of the insulin infusion resulted in: (1) a rapid (already significant after 1 h) and sustained (maximal fall: --12.5 +/- 2.5 mU/L at 3 a.m.) decrease in plasma free insulin; (2) a delayed (significant after 4 h) and linear rise in blood glucose (maximal increase: + 4.0 +/- 1.3 mmol/L at 5 a.m.); (3) an early (significant at midnight) and prolonged rise in plasma free fatty acids (+ 387 +/- 148 mumol/L at 3 a.m.); (4) a delayed (significant after 3 h) and sustained increase in plasma 3 OH-B (+ 347 +/- 88 mumol/L at 3 a.m.); and (5) no significant changes in plasma glucagon. Thus, a 2-h interruption of CSII in resting nocturnal conditions is sufficient to induce significant, delayed, and sustained metabolic alterations in C-peptide-negative patients despite good baseline blood glucose control. Resetting the pump at its basal rate is insufficient to quickly restore adequate circulating insulin levels and effectively counteract the metabolic disturbances. The efficacy of a bolus insulin injection in these conditions should be evaluated.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6381007     DOI: 10.2337/diacare.7.4.338

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  5 in total

1.  Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patients.

Authors:  A J Scheen; J Gillet; J Rosenthaler; J Guiot; P Henrivaux; B Jandrain; P J Lefèbvre
Journal:  Diabetologia       Date:  1989-11       Impact factor: 10.122

2.  Innovations in technology for the treatment of diabetes: clinical development of the artificial pancreas (an autonomous system).

Authors:  David C Klonoff; Charles L Zimliki; Lcdr Alan Stevens; Patricia Beaston; Arleen Pinkos; Sally Y Choe; Guillermo Arreaza-Rubín; William Heetderks
Journal:  J Diabetes Sci Technol       Date:  2011-05-01

3.  Long-term safety, efficacy and side-effects of continuous subcutaneous insulin infusion treatment for type 1 (insulin-dependent) diabetes mellitus: a one centre experience.

Authors:  E Chantelau; M Spraul; I Mühlhauser; R Gause; M Berger
Journal:  Diabetologia       Date:  1989-07       Impact factor: 10.122

Review 4.  Pharmacokinetics of insulin. Implications for continuous subcutaneous insulin infusion therapy.

Authors:  E W Kraegen; D J Chisholm
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

5.  Prevention of nocturnal hypoglycemia using predictive alarm algorithms and insulin pump suspension.

Authors:  Bruce Buckingham; H Peter Chase; Eyal Dassau; Erin Cobry; Paula Clinton; Victoria Gage; Kimberly Caswell; John Wilkinson; Fraser Cameron; Hyunjin Lee; B Wayne Bequette; Francis J Doyle
Journal:  Diabetes Care       Date:  2010-03-03       Impact factor: 19.112

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.